Original language | English (US) |
---|---|
Pages (from-to) | 1082-1089.e4 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 4 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2006 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin. / Wilcox, C. Mel; Allison, Jeroan; Benzuly, Keith et al.
In: Clinical Gastroenterology and Hepatology, Vol. 4, No. 9, 09.2006, p. 1082-1089.e4.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin
AU - Wilcox, C. Mel
AU - Allison, Jeroan
AU - Benzuly, Keith
AU - Borum, Marie
AU - Cryer, Byron
AU - Grosser, Tilo
AU - Hunt, Richard
AU - Ladabaum, Uri
AU - Lanas, Angel
AU - Paulus, Harold
AU - Regueiro, Carol
AU - Sandler, Robert S.
AU - Simon, Lee
N1 - Funding Information: Byron Cryer has served as a Consultant to AstraZeneca, TAP Pharmaceuticals, and Pfizer, Inc. Richard Hunt discloses having been a Consultant at some time to Merck, Pfizer, Novartis, AstraZeneca, TAP, Santarus, and Altana, and a past investigator for Merck, Novartis, AstraZeneca, TAP, and Altana. Angel Lanas has received grants and travel support from AstraZeneca, Takeda, and Pfizer, and he is a Board Member of the APPROVE Trial by Merck & Company. Harold Paulus has had no financial conflicts of interest in the past 3 years, although he has prior consultancies with many pharmaceutical companies. Robert S. Sandler is a Consultant to Merck, Bayer, Takeda, and GlaxoSmithKline, and has received grant support from Merck. Lee Simon has received speaking honoraria from Academy of Healthcare, Pfizer, Avanir, and the Foundation for Better Healthcare, and he has been a Consultant to AstraZeneca, Cerimon, Alpha Rx, Proprius, Avanir, Novartis, Pfizer, Aldolor, Paraexel, Affinergy, Aai pharma, Alder, Cell Therapeutics, Altea, Chelsea Pharmaceuticals, Cure, Coley, Puretech Ventures, Solace Pharmaceuticals, Nuvo, Dr Reddy’s, Genelabs, Jazz, Medimmune, Neopharm, Neuromed, Nitec, Nomura Ventures, Purdue, Sepracor, Serono, Savient, Polymerix, Rigel, Roche, TAP, and Zydus.
PY - 2006/9
Y1 - 2006/9
UR - http://www.scopus.com/inward/record.url?scp=33748165573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748165573&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2006.04.010
DO - 10.1016/j.cgh.2006.04.010
M3 - Article
C2 - 16877048
AN - SCOPUS:33748165573
SN - 1542-3565
VL - 4
SP - 1082-1089.e4
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 9
ER -